{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T02:58:52Z","timestamp":1791773932079,"version":"4.3.4"},"reference-count":106,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T00:00:00Z","timestamp":1674691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010089","name":"JGW Patterson Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010089","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012295","name":"NIHR Newcastle Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012295","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Checkpoint inhibitors (CPIs) are monoclonal antibodies which, by disrupting interactions of immune checkpoint molecules with their ligands, block regulatory immune signals otherwise exploited by cancers. Despite revolutionary clinical benefits, CPI use is associated with an array of immune-related adverse events (irAEs) that mirror spontaneous autoreactivity. Severe irAEs necessitate pausing or stopping of CPI therapy and use of corticosteroids and\/or other immunomodulatory interventions. Despite increasingly widespread CPI use, irAE pathobiology remains poorly understood; its elucidation may point to targeted mitigation strategies and uncover predictive biomarkers for irAE onset in patients, whilst casting new light on mechanisms of spontaneous immune-mediated disease. This review focuses on common CPI-induced irAEs of the gut, skin and synovial joints, and how these compare to immune-mediated diseases such as ulcerative colitis, vitiligo and inflammatory arthritis. We review current understanding of the immunological changes reported following CPI therapy at the level of peripheral blood and tissue. Many studies highlight dysregulation of cytokines in irAE-affected tissue, particularly IFN\u03b3 and TNF. IrAE-affected tissues are also predominantly infiltrated by T-cells, with low B-cell infiltration. Whilst there is variability between studies, patients treated with anti-programmed cell death-1 (PD-1)\/PDL-1 therapies seem to exhibit CD8+ T-cell dominance, with CD4+ T-cells dominating in those treated with anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) monotherapy. Interestingly, CD8+CXCR3+ T-cells have been reported to be elevated in gastrointestinal, dermatological and musculoskeletal -irAE affected tissues. These findings may highlight potential opportunities for therapeutic development or re-deployment of existing therapies to prevent and\/or improve the outcome of irAEs.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1122430","type":"journal-article","created":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T10:07:27Z","timestamp":1674727647000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":27,"title":["Immune-related adverse events in checkpoint blockade: Observations from human tissue and therapeutic considerations"],"prefix":"10.3389","volume":"14","author":[{"given":"Kristian C.","family":"Williams","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"Gault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy E.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher A.","family":"Lamb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Ally","family":"Speight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Rajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Plummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur G.","family":"Pratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.molmed.2014.10.009","article-title":"Human cancer immunotherapy with antibodies to the pd-1 and pd-L1 pathway","volume":"21","author":"Ohaegbulam","year":"2015","journal-title":"Trends Mol Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune checkpoint inhibitors for the treatment of cancer: Clinical impact and mechanisms of response and resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu Rev Pathol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: Esmo clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s40425-018-0346-6","article-title":"Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: Retrospective review at md Anderson","volume":"6","author":"Wang","year":"2018","journal-title":"J ImmunoTher Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-019-02303-1","article-title":"Immune checkpoint inhibitor-induced colitis as a predictor of survival in metastatic melanoma","volume":"68","author":"Abu-Sbeih","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v28.i39.5750","article-title":"Immune checkpoint inhibitor-mediated colitis is associated with cancer overall survival","volume":"28","author":"Weingarden","year":"2022","journal-title":"World J Gastroenterol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1186\/s12967-020-02612-5","article-title":"Revisiting the association between skin toxicity and better response in advanced cancer patients treated with immune checkpoint inhibitors","volume":"18","author":"Gulati","year":"2020","journal-title":"J Trans Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"keac519","DOI":"10.1093\/rheumatology\/keac519","article-title":"Immune checkpoint inhibitor\u2013induced arthralgia is tightly associated with improved overall survival in cancer patients","author":"Maeda","year":"2022","journal-title":"Rheumatology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/1756-185X.13444","article-title":"Association of good oncological response to therapy with the development of rheumatic immune-related adverse events following pd-1 inhibitor therapy","volume":"22","author":"Liew","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"B10","unstructured":"Common terminology criteria for adverse events2021"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: Asco guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for immunotherapy of cancer (Sitc) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J ImmunoTher Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.0012","article-title":"Nccn guidelines insights: Management of immunotherapy-related toxicities, version 1.2020","volume":"18","author":"Thompson","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00296-0","article-title":"Hitting the sweet spot: Optimal use of corticosteroids for immune checkpoint inhibitor side-effects","volume":"23","author":"Schmitt","year":"2022","journal-title":"Lancet Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31629","article-title":"High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma","volume":"124","author":"Faje","year":"2018","journal-title":"Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.06.004","article-title":"Early use of systemic corticosteroids in patients with advanced nsclc treated with nivolumab","volume":"13","author":"Scott","year":"2018","journal-title":"J Thorac Oncol"},{"key":"B17","unstructured":"National cancer drugs fund list2022"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(20)30014-5","article-title":"British Society of gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis","volume":"5","author":"Powell","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30700-9","article-title":"Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (Checkmate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial","volume":"19","author":"Hodi","year":"2018","journal-title":"Lancet Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801946","article-title":"Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden","volume":"378","author":"Hellmann","year":"2018","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30231-0","article-title":"Ipilimumab 10 Mg\/Kg versus ipilimumab 3 Mg\/Kg in patients with unresectable or metastatic melanoma: A randomised, double-blind, multicentre, phase 3 trial","volume":"18","author":"Ascierto","year":"2017","journal-title":"Lancet Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-Small-Cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.18.00005","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline summary","volume":"14","author":"Brahmer","year":"2018","journal-title":"J Oncol practice\/American Soc Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","article-title":"Management of toxicities of immune checkpoint inhibitors","volume":"44","author":"Spain","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v27.i41.7190","article-title":"Clinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survival","volume":"27","author":"Yamada","year":"2021","journal-title":"World J Gastroenterol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.08.063","article-title":"Aga clinical practice update on diagnosis and management of immune checkpoint inhibitor colitis and hepatitis: Expert review","volume":"160","author":"Dougan","year":"2021","journal-title":"Gastroenterology"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e002742","DOI":"10.1136\/jitc-2021-002742","article-title":"Clinical outcomes of patients with corticosteroid refractory immune checkpoint inhibitor-induced enterocolitis treated with infliximab","volume":"9","author":"Alexander","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B32","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-018-0411-1","article-title":"Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis","volume":"6","author":"Abu-Sbeih","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2017-000278","article-title":"Immune checkpoint inhibition-related colitis: Symptoms, endoscopic features, histology and response to management","volume":"3","author":"Geukes Foppen","year":"2018","journal-title":"ESMO Open"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izy240","article-title":"Can immune checkpoint inhibitors induce microscopic colitis or a brand new entity","volume":"25","author":"Choi","year":"2019","journal-title":"Inflammation Bowel Dis"},{"key":"B35","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1186\/s40425-019-0756-0","article-title":"Budesonide treatment for microscopic colitis from immune checkpoint inhibitors","volume":"7","author":"Hughes","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005490","article-title":"Oral beclomethasone dipropionate is an effective treatment for immune checkpoint inhibitor induced colitis","volume":"10","author":"Alexander","year":"2022","journal-title":"J ImmunoTher Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01695-5","article-title":"Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma","volume":"28","author":"Lee","year":"2022","journal-title":"Nat Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti-Pd-1 immunotherapy in melanoma patients","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science"},{"key":"B39","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1126\/science.abf3363","article-title":"Fecal microbiota transplant overcomes resistance to anti-Pd-1 therapy in melanoma patients","volume":"371","author":"Davar","year":"2021","journal-title":"Science"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.913217","article-title":"Fecal microbiota transplantation effectively cures a patient with severe bleeding immune checkpoint inhibitor-associated colitis and a short review","volume":"12","author":"Chen","year":"2022","journal-title":"Front Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djaa057","article-title":"Association of antibiotic exposure with survival and toxicity in patients with melanoma receiving immunotherapy","volume":"113","author":"Mohiuddin","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1001623","article-title":"Interaction between gut microbiota and immune checkpoint inhibitor-related colitis","volume":"13","author":"Zhou","year":"2022","journal-title":"Front Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1080\/07357907.2017.1324032","article-title":"Immunological characteristics of colitis associated with anti-Ctla-4 antibody therapy","volume":"35","author":"Bamias","year":"2017","journal-title":"Cancer Invest"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjx081","article-title":"Colon immune-related adverse events: Anti-Ctla-4 and anti-Pd-1 blockade induce distinct immunopathological entities","volume":"11","author":"Coutzac","year":"2017","journal-title":"J Crohns Colitis"},{"key":"B45","doi-asserted-by":"publisher","first-page":"e157839","DOI":"10.1172\/jci.insight.157839","article-title":"Distinct pre-treatment innate immune landscape and post-treatment T cell responses underlie immunotherapy-induced colitis","volume":"7","author":"Nahar","year":"2022","journal-title":"JCI Insight"},{"key":"B46","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.cell.2020.06.001","article-title":"Molecular pathways of colon inflammation induced by cancer immunotherapy","volume":"182","author":"Luoma","year":"2020","journal-title":"Cell"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20130579","article-title":"Fc-dependent depletion of tumor-infiltrating regulatory T cells Co-defines the efficacy of anti-Ctla-4 therapy against melanoma","volume":"210","author":"Simpson","year":"2013","journal-title":"J Exp Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1417320112","article-title":"Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients","volume":"112","author":"Romano","year":"2015","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0762","article-title":"Anti-Ctla-4 immunotherapy does not deplete Foxp3(+) regulatory T cells (Tregs) in human cancers","volume":"25","author":"Sharma","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-009-0839-8","article-title":"Refractory colitis following anti-Ctla4 antibody therapy: Analysis of mucosal Foxp3+ T cells","volume":"55","author":"Lord","year":"2010","journal-title":"Dig Dis Sci"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13502","article-title":"Mucosal-associated invariant T (Mait) cells are activated in the gastrointestinal tissue of patients with combination ipilimumab and nivolumab therapy-related colitis in a pathology distinct from ulcerative colitis","volume":"202","author":"Sasson","year":"2020","journal-title":"Clin Exp Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.13242","article-title":"Mait cells are activated and accumulated in the inflamed mucosa of ulcerative colitis","volume":"31","author":"Haga","year":"2016","journal-title":"J Gastroenterol Hepatol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s40425-015-0081-1","article-title":"Baseline circulating il-17 predicts toxicity while tgf-Beta1 and il-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma","volume":"3","author":"Tarhini","year":"2015","journal-title":"J Immunother Cancer"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.29.15_suppl.2505","article-title":"Evaluation of serum il-17 levels during ipilimumab therapy: Correlation with colitis","volume":"29","author":"Callahan","year":"2011","journal-title":"J Clin Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1111\/cup.12858","article-title":"Diverse types of dermatologic toxicities from immune checkpoint blockade therapy","volume":"44","author":"Curry","year":"2017","journal-title":"J Cutan Pathol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19750","article-title":"Cutaneous immune-related adverse events in patients with melanoma treated with checkpoint inhibitors","volume":"185","author":"Gault","year":"2021","journal-title":"Br J Dermatol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.04.105","article-title":"Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features","volume":"83","author":"Ellis","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2021.06.040","article-title":"Immune checkpoint blockade and skin toxicity pathogenesis","volume":"142","author":"Ma","year":"2022","journal-title":"J Invest Dermatol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00311","article-title":"Corrigendum: Current diagnosis and management of immune related adverse events (Iraes) induced by immune checkpoint inhibitor therapy","volume":"8","author":"Kumar","year":"2017","journal-title":"Front Pharmacol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","article-title":"Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-Pd-1 therapy","volume":"60","author":"Hofmann","year":"2016","journal-title":"Eur J Cancer"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2017.04.019","article-title":"Vitiligo in a patient with lung adenocarcinoma treated with nivolumab: A case report","volume":"109","author":"Uenami","year":"2017","journal-title":"Lung Cancer"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-20-386","article-title":"Vitiligo-like depigmentation after pembrolizumab treatment in patients with non-small cell lung cancer: A case report","volume":"9","author":"Yun","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000013810","article-title":"Vitiligo-like lesions in a patient treated with nivolumab for renal cell carcinoma","volume":"97","author":"Lolli","year":"2018","journal-title":"Med (Baltimore)"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.9568","article-title":"The effect of the microbiome on immune checkpoint inhibitor toxicity in patients with melanoma","volume":"40","author":"Williams","year":"2022","journal-title":"J Clin Oncol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2021.08.021","article-title":"The skin microbiome and the gut-skin axis","volume":"39","author":"Sinha","year":"2021","journal-title":"Clin Dermatol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.13540","article-title":"Histopathological aspects of cutaneous erythematous-papular eruptions induced by immune checkpoint inhibitors for the treatment of metastatic melanoma","volume":"56","author":"Perret","year":"2017","journal-title":"Int J Dermatol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1111\/cup.12666","article-title":"Immunohistochemical analysis of lichenoid reactions in patients treated with anti-Pd-L1 and anti-Pd-1 therapy","volume":"43","author":"Schaberg","year":"2016","journal-title":"J Cutan Pathol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1158\/2326-6066.CIR-14-0134","article-title":"Lichenoid dermatitis in three patients with metastatic melanoma treated with anti-Pd-1 therapy","volume":"3","author":"Joseph","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2016.2226","article-title":"Clinical and histologic features of lichenoid mucocutaneous eruptions due to anti-programmed cell death 1 and anti-programmed cell death ligand 1 immunotherapy","volume":"152","author":"Shi","year":"2016","journal-title":"JAMA Dermatol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2872","article-title":"Cytotoxic cutaneous adverse drug reactions during anti-Pd-1 therapy","volume":"22","author":"Goldinger","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.10.044","article-title":"Vitiligo-like lesions occurring in patients receiving anti-programmed cell death-1 therapies are clinically and biologically distinct from vitiligo","volume":"76","author":"Larsabal","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14143","article-title":"Bullous pemphigoid associated with nivolumab, a programmed cell death 1 protein inhibitor","volume":"31","author":"Kwon","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0123","article-title":"Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting pd-1 and pd-L1","volume":"4","author":"Naidoo","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B74","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.lungcan.2017.04.020","article-title":"Aprepitant for refractory nivolumab-induced pruritus","volume":"109","author":"Ito","year":"2017","journal-title":"Lung Cancer"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.36849\/JDD.6559","article-title":"Case series of stevens-Johnson syndrome and toxic epidermal necrolysis with nivolumab and nivolumab\/ ipilimumab combination therapy in metastatic melanoma","volume":"21","author":"Lee","year":"2022","journal-title":"J Drugs Dermatol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.03.029","article-title":"Generalized bullous mucocutaneous eruption mimicking stevens-Johnson syndrome in the setting of immune checkpoint inhibition: A multicenter case series","volume":"83","author":"Molina","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212257","article-title":"Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: A single-centre prospective cohort study","volume":"77","author":"Kostine","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez536","article-title":"Management of rheumatic complications of immune checkpoint inhibitor therapy - an oncological perspective","volume":"58","author":"Steven","year":"2019","journal-title":"Rheumatology"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2018.02.011","article-title":"Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen","volume":"48","author":"Cappelli","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"B80","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1136\/annrheumdis-2020-217139","article-title":"Eular points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors","volume":"80","author":"Kostine","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23177","article-title":"Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: A systematic review of the literature","volume":"69","author":"Cappelli","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1038\/s41467-022-29539-3","article-title":"Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy","volume":"13","author":"Kim","year":"2022","journal-title":"Nat Commun"},{"key":"B83","doi-asserted-by":"publisher","first-page":"e000281","DOI":"10.1136\/jitc-2019-000281","article-title":"Nivolumab-induced synovitis is characterized by florid T cell infiltration and rapid resolution with synovial biopsy-guided therapy","volume":"8","author":"Murray-Brown","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000001088","article-title":"Thinking inside the box: Synovial tissue biopsy in immune checkpoint inhibitor-induced arthritis","volume":"27","author":"Medina","year":"2021","journal-title":"J Clin Rheumatol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s40425-019-0597-x","article-title":"Recurrent pseudogout after therapy with immune checkpoint inhibitors: A case report with immunoprofiling of synovial fluid at each flare","volume":"7","author":"Kim","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B86","doi-asserted-by":"publisher","first-page":"464961","DOI":"10.1101\/2021.10.19.464961","article-title":"Clonally expanded Cd38hi cytotoxic Cd8 T cells define the T cell infiltrate in checkpoint inhibitor-associated arthritis","author":"Wang","year":"2021","journal-title":"bioRxiv"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1002\/art.41156","article-title":"Polyfunctional, proinflammatory, tissue-resident memory phenotype and function of synovial interleukin-17a+Cd8+ T cells in psoriatic arthritis","volume":"72","author":"Steel","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-2324","article-title":"Immune toxicities elicted by ctla-4 blockade in cancer patients are associated with early diversification of the T-cell repertoire","volume":"77","author":"Oh","year":"2016","journal-title":"Cancer Res"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-SITC2022.0441","article-title":"441 checkpoint inhibitor-associated inflammatory arthritis is comprised of multiple clinical endotypes characterized by distinct transcriptional programs","volume":"10","author":"Reynolds","year":"2022","journal-title":"J ImmunoTher Cancer"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1172\/JCI96798","article-title":"Early b cell changes predict autoimmunity following combination immune checkpoint blockade","volume":"128","author":"Das","year":"2018","journal-title":"J Clin Invest"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1011040","article-title":"External validation of biomarkers for immune-related adverse events after immune checkpoint inhibition","volume":"13","author":"Glehr","year":"2022","journal-title":"Front Immunol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"e001161","DOI":"10.1136\/jitc-2020-002261","article-title":"Timing of steroid initiation and response rates to immune checkpoint inhibitors in metastatic cancer","volume":"9","author":"Maslov","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B93","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1001\/jamaoncol.2022.5041","article-title":"Association of immune-related adverse event management with survival in patients with advanced melanoma","volume":"8","author":"van Not","year":"2022","journal-title":"JAMA Oncol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-020-02382-6","article-title":"Trends in long-term glucocorticoid use and risk of 5-year mortality: A historical cohort study in south Korea","volume":"69","author":"Oh","year":"2020","journal-title":"Endocrine"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1002\/art.38210","article-title":"Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis","volume":"66","author":"del Rincon","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.918356","article-title":"High mortality rate in oral glucocorticoid users: A population-based matched cohort study","volume":"13","author":"Einarsdottir","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30828-3","article-title":"New therapeutic perspectives to manage refractory immune checkpoint-related toxicities","volume":"20","author":"Martins","year":"2019","journal-title":"Lancet Oncol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000268","article-title":"Incidence and clinical impact of anti-tnfalpha treatment of severe immune checkpoint inhibitor-induced colitis in advanced melanoma: The mecolit survey","volume":"42","author":"Lesage","year":"2019","journal-title":"J Immunother"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1988.6.8.1328","article-title":"A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients","volume":"6","author":"Feinberg","year":"1988","journal-title":"J Clin Oncol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1038\/10552","article-title":"Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis","volume":"5","author":"Moore","year":"1999","journal-title":"Nat Med"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2017.4332","article-title":"Malignant neoplasms in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors, tocilizumab, abatacept, or rituximab in clinical practice: A nationwide cohort study from Sweden","volume":"177","author":"Wadstrom","year":"2017","journal-title":"JAMA Intern Med"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20151255","article-title":"Anti-tnf drives regulatory T cell expansion by paradoxically promoting membrane tnf-Tnf-Rii binding in rheumatoid arthritis","volume":"213","author":"Nguyen","year":"2016","journal-title":"J Exp Med"},{"key":"B103","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ejim.2021.07.016","article-title":"Tocilizumab for the treatment of immune-related adverse events: A systematic literature review and a multicentre case series","volume":"93","author":"Campochiaro","year":"2021","journal-title":"Eur J Intern Med"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1097\/DER.0000000000000776","article-title":"Systemic treatment of cutaneous adverse events after immune checkpoint inhibitor therapy: A review","author":"Brown","year":"2021","journal-title":"Dermatitis"},{"key":"B105","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1038\/s41467-022-30863-x","article-title":"Regulatory b cell repertoire defects predispose lung cancer patients to immune-related toxicity following checkpoint blockade","volume":"13","author":"Patel","year":"2022","journal-title":"Nat Commun"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1038\/d41587-021-00002-w","article-title":"Fecal microbiota potentiate checkpoint inhibitors, unleash microbiome startups","volume":"39","author":"Zipkin","year":"2021","journal-title":"Nat Biotechnol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1122430\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T10:07:32Z","timestamp":1674727652000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1122430\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,26]]},"references-count":106,"alternative-id":["10.3389\/fimmu.2023.1122430"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1122430","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,26]]},"article-number":"1122430"}}